<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03411954</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-2017-209</org_study_id>
    <nct_id>NCT03411954</nct_id>
  </id_info>
  <brief_title>Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients:an Open, Prospective,Non-randomized Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized phase III study observing the cognitive function
      changes with conformal hippocampus avoidance during intensity modulated radiotherapy for T4
      nasopharyngeal carcinoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received intensity modulated radiotherapy or Tomotherapy with or without
      chemotherapy. Before radiotherapy, the patients will receive brain MRI scanning and the brain
      MRI images will be fused with the head and neck CT scan images. The investigators develop the
      treatment plan with hippocampus avoidance. Cognitive function are evaluated before,during and
      after radiotherapy. Dose-volume Histograms are got to analyze the associated factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the dose-volume relationship between hippocampus and cognitive function</measure>
    <time_frame>1 year</time_frame>
    <description>To explore the relationship between cognitive impairment and exposure dose of hippocampus in patients with nasopharyngeal carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive function changes</measure>
    <time_frame>1 year</time_frame>
    <description>response to the Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>memory function changes</measure>
    <time_frame>1 year</time_frame>
    <description>response to the Hopkins Verbal Learning Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>response to the QLQ-C30</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>HP-RT</arm_group_label>
    <description>Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        100
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologic confirmed nasopharyngeal carcinoma

          2. ECOG performance scale 0-2

          3. Tumor stage is T4N0-3M0-1 according to 8th American Joint Commission on Cancer edition

          4. Adequate hepatic, renal and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥
             100×10^9/L, neutrophils ≥ 1.5×10^9/L, serum transaminase &lt; 2.5×the upper limit of
             normal(ULN), (If liver metastases, serum transaminase&lt; 5×the ULN), creatinine
             clearance rate ＞ 60ml/min.

          5. Informed consent signed.

        Exclusion Criteria:

          1. History of malignant tumors.

          2. Any severe complications contraindicated chemotherapy or radiotherapy.

          3. Medical history of central nervous system, cognitive or psychological diseases;

          4. Pregnant or nursing women.

          5. Patients with mental disease cannot complete the questionaire.

          6. MRI contraindication -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuanyaun chen, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yuanyuan chen, professor</last_name>
    <phone>+86 13738103808</phone>
    <email>chenyy@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuanyuan chen, Professor</last_name>
      <phone>+86 13738103808</phone>
      <email>chenyy@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hippocampus avoidance</keyword>
  <keyword>cognitive changes</keyword>
  <keyword>intensity modulated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

